This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. OPGN, ENZ, SLS, TVRD, PRQR, SGHT, NGNE, OABI, CRDF, and MDWDShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), Enzo Biochem (ENZ), SELLAS Life Sciences Group (SLS), Tvardi Therapeutics (TVRD), ProQR Therapeutics (PRQR), Sight Sciences (SGHT), Neurogene (NGNE), OmniAb (OABI), Cardiff Oncology (CRDF), and MediWound (MDWD). These companies are all part of the "medical" sector. Miragen Therapeutics vs. Its Competitors OpGen Enzo Biochem SELLAS Life Sciences Group Tvardi Therapeutics ProQR Therapeutics Sight Sciences Neurogene OmniAb Cardiff Oncology MediWound Miragen Therapeutics (NASDAQ:MGEN) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Does the media prefer MGEN or OPGN? In the previous week, Miragen Therapeutics' average media sentiment score of 0.00 equaled OpGen'saverage media sentiment score. Company Overall Sentiment Miragen Therapeutics Neutral OpGen Neutral Do insiders & institutionals have more ownership in MGEN or OPGN? 2.7% of OpGen shares are held by institutional investors. 1.1% of Miragen Therapeutics shares are held by company insiders. Comparatively, 43.8% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, MGEN or OPGN? Miragen Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.66, meaning that its share price is 266% less volatile than the S&P 500. Is MGEN or OPGN more profitable? OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Miragen Therapeutics-1,393.50% -141.66% -88.74% OpGen -1,140.36%N/A -287.58% Which has higher earnings and valuation, MGEN or OPGN? OpGen has lower revenue, but higher earnings than Miragen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiragen Therapeutics$4.46M13.92-$41.87M-$20.09-0.79OpGen$2.67M18.57-$32.67MN/AN/A SummaryOpGen beats Miragen Therapeutics on 6 of the 9 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.10M$22.63M$5.47B$8.92BDividend YieldN/A119.72%5.24%4.04%P/E Ratio-1.49N/A27.0520.14Price / Sales13.927.00380.7693.83Price / CashN/AN/A26.2128.59Price / Book2.340.218.005.58Net Income-$41.87M-$27.15M$3.16B$248.40M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$15.89+1.4%N/A+27.2%$62.10M$4.46M-1.4945High Trading VolumeOPGNOpGenN/A$4.76-0.4%N/A+88.0%$47.92M$2.67M0.00100Gap DownENZEnzo BiochemN/A$0.33-14.8%N/A-69.3%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeSLSSELLAS Life Sciences Group0.1236 of 5 stars$2.08-5.0%N/A+79.3%$218.51M$1M0.0010News CoverageTVRDTvardi TherapeuticsN/A$22.15-5.1%$71.50+222.8%N/A$218.39M$7.14M0.0080PRQRProQR Therapeutics2.1135 of 5 stars$2.01-1.5%$8.00+298.0%+25.9%$214.63M$20.46M-5.74180News CoverageSGHTSight Sciences1.386 of 5 stars$4.07-1.5%$4.10+0.7%-44.0%$213.50M$79.87M0.00210News CoverageNGNENeurogene3.7905 of 5 stars$19.19+28.4%$46.17+140.6%-42.9%$213.22M$930K0.0090Positive NewsHigh Trading VolumeOABIOmniAb2.5994 of 5 stars$1.74flat$7.00+302.3%-51.0%$212.51M$26.39M0.007CRDFCardiff Oncology1.6974 of 5 stars$3.51+11.4%$9.88+181.3%+65.2%$209.56M$680K-3.8220Analyst ForecastHigh Trading VolumeMDWDMediWound1.6372 of 5 stars$19.20-0.9%$31.80+65.6%-1.7%$209.35M$20.22M-9.1980News Coverage Related Companies and Tools Related Companies OpGen Alternatives Enzo Biochem Alternatives SELLAS Life Sciences Group Alternatives Tvardi Therapeutics Alternatives ProQR Therapeutics Alternatives Sight Sciences Alternatives Neurogene Alternatives OmniAb Alternatives Cardiff Oncology Alternatives MediWound Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGEN Stock Alerts